See today's BioWorld Asia
To read the full story, subscribe or sign in.

Biotheus, Hansoh ink potential ¥5B deal for new bispecific ADCs

March 19, 2024
By Marian (YoonJee) Chu
Chinese biotechs Biotheus Inc. and Hansoh Pharmaceutical Group Co. Ltd. partnered again under a new potential ¥5 billion (US$698.98 million) deal to develop bispecific antibody-drug conjugates (BsADCs), using Biotheus’ EGFR-cMet bispecific antibody.
BioWorld Asia Deals and M&A Cancer Antibody-drug conjugate Bispecific antibody Asia-Pacific